- Q4 2023 InflaRx NV Earnings Call TranscriptMar 21, 2024€1.43 (-9.51%)Earnings
- InflaRx NV Conference Call TranscriptJan 04, 2024
- InflaRx NV at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- InflaRx NV Corporate Call TranscriptSep 11, 2023
- InflaRx NV PANAMO Ph3 Results Call TranscriptMar 31, 2022
- InflaRx NV Virtual R&D Event TranscriptFeb 03, 2022
- InflaRx NV at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Inflarx NV at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 10, 2021
- Inflarx NV Pyoderma Gangrenosum Cohort Three Top-Line Results Conference Call TranscriptOct 27, 2021
- Inflarx NV at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 23, 2021
- Inflarx NV at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Inflarx NV at JPMorgan Healthcare Conference TranscriptJan 16, 2020
- Q3 2019 Inflarx NV Earnings Call TranscriptNov 07, 2019€2.44 (+1.67%)Earnings
- InflaRx N.V. - Special Call TranscriptJul 19, 2019
Inflarx NV at Raymond James Human Health Innovation Conference (Virtual) Transcript
Well, good morning and welcome, everyone, to the next session at the Raymond James Human Health Innovation Conference. I am Steve Seedhouse. It really is a pleasure for me to welcome the next participating company at our conference, InflaRx. InflaRx is a biotech company developing an anti-C5a antibody, vilobelimab or IFX-1, formally for inflammatory immune disorders. And I'm joined by, of course, CEO, Niels Riedemann; and Chief Strategy Officer, Jordan Zwick; and really looking forward to our virtual fireside chat.
So I would just also mention that listeners are invited to submit questions if you'd like via OpenExchange or you can email me directly.
Questions & Answers
But with that, would like to just hop right into it. And Niels, I wanted to start with your Hidradenitis Suppurativa program. Talk about basically the latest update, which was essentially that the FDA remains committed to HiSCR endpoint, which is what you used in your Phase II
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)